IL2 and neoplasm: These data suggest that TransCon TLR7/8 Agonist treatment may promote tumor antigen presentation and priming of tumor-specific cytotoxic T cells associated with treated tumors, while IL-2 may promote further expansion of said tumor-specific CD8 T cells, allowing them to exert systemic tumor killing activity, resulting in regression of tumors not treated with TransCon TLR7/8 Agonist.